Jubilant Life Sciences’ arm launches remdesivir for COVID-19 treatment in India

04 Aug 2020 Evaluate

Jubilant Life Sciences’ subsidiary -- Jubilant Generics has launched remdesivir for injection under the brand name ‘JUBIR’ in the Indian market at a price of Rs 4,700 per vial of 100 mg (lyophilized injection). The company will make the drug available to over 1,000 hospitals providing COVID-19 treatment in India through its distribution network. The company’s 24 hour help line will enhance access to ‘JUBIR’ during these pandemic times, where timely access to the drug may prove critical to treatment outcomes.

In order to increase accessibility of ‘JUBIR’ to patients below the poverty line and to front line paramedical staff, Jubilant Bhartia Foundation, a not-for-profit organisation of Jubilant Group, is launching unique programs in India aimed at distribution of the drug.

Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.

Jubilant Pharmova Share Price

995.15 -51.50 (-4.92%)
19-Jan-2026 15:17 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1674.85
Dr. Reddys Lab 1165.40
Cipla 1391.40
Zydus Lifesciences 881.95
Lupin 2178.75
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×